Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
about
The role of antiplatelet therapy in the management of acute coronary syndromesGlycoprotein receptor inhibitors in the management of acute coronary syndromesClinical trials of glycoprotein IIb/IIIa inhibitorsRole of abciximab in the treatment of coronary artery diseaseEvaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndromeCoronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.Function-modulating human monoclonal antibodies against platelet-membrane receptors isolated from a phage-display library.Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction.Safety evaluation of tirofiban.Safety and Efficacy of Intravenous Tirofiban as Antiplatelet Premedication for Stent-Assisted Coiling in Acutely Ruptured Intracranial Aneurysms.A New Protocol for Anticoagulation With Tirofiban During Flow Diversion.ABCIXIMAB: a new antiaggregant used in angioplasty.The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.Platelet adhesion receptors: novel targets for anti-thrombotic therapy.Platelet activation in acute myocardial infarction and the rationale for combination therapy.Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications.Advances in haematological pharmacotherapy in 21st century.The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy.The use of the glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention.Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes.Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.Bench to bedside: pathophysiology of acute coronary syndromes and implications for therapy.Vipegitide: a folded peptidomimetic partial antagonist of α2β1 integrin with antiplatelet aggregation activity.Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.Coronary artery perforation during percutaneous intervention: incidence and outcomeShould glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesStarve a tumor: therapeutic advice for breast cancer?Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit.Safety of Abciximab injection during endovascular treatment of ruptured aneurysms.Rationale for intracoronary administration of abciximab.The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.
P2860
Q28176548-306631FC-E78E-4DDC-8394-A1E2C6C01B2AQ28193156-CBB7D29F-25CE-457E-BA1E-DC403AB3AC8CQ28193162-5D3F5C8C-4D84-4C8E-9500-28F930EC2041Q28200177-E0BEE84E-BC48-4C13-96D1-4ECE2E89A08BQ28210450-E8375C0C-6408-4B34-A96B-B47B67925A75Q30658145-D45C42B8-F004-461E-A86C-EE595BC3978DQ31153606-68CEC2BB-3B8A-4EFF-B104-10014222F3AFQ33333453-8085CB89-B73E-48FC-889E-DB34BDBF8866Q33339038-40A00AA0-0BD1-45B0-8F82-1F5F4F5A99FDQ33365571-43F33170-88AB-4838-8422-9AC646D8EF90Q33369310-B4DED3C2-04DA-4FB2-9AD7-6664559F3351Q33391065-766D1D0A-D7CA-4A2B-8E4D-BA15BCF21E6CQ33426776-28BC20B2-99A6-47C3-A383-0E67EAE4808EQ33426924-68D6D028-5F58-443A-AB30-48C9C3B33FF0Q33497071-E1FF4A7E-8A68-4376-9DE0-2CDFDFDD6377Q33689211-E80B2464-30C9-444A-8CD8-651D245A3E74Q33951293-3478F9CC-5CDB-4136-994E-23D0E9F5FC5AQ34027520-FB16F631-3DAD-4BAE-8EEA-32B5990DAE3EQ34027525-5B4B489E-9CA3-4995-8FD6-B53104529229Q34061211-3FB65F8E-76D5-4F66-A020-2E2D0705245AQ34406838-344EEA56-43DA-42A5-BD47-014C625D43E3Q34675284-2EFE1D92-613E-4AE0-A271-DE93913644A7Q34675287-7DCFB132-3885-472D-90C5-1D36DACE1505Q34675290-635D95D4-2E6F-4E03-890F-65EE1A83D974Q34684081-8CAA4B49-9A7A-44B3-BA03-065404677D18Q34716730-27382E69-69F9-4D9F-90DF-20B91DC4008AQ34930685-9894771F-A06F-499A-AD54-A89432C7162FQ34954267-DF53EB1D-3D75-4C0E-8DD1-B0AA08CCF30BQ35008537-ED523F20-F458-41D9-96DE-1DB4E0C0B376Q35139249-527C71AA-3182-450B-9DBB-596A16ADDF45Q35152095-5B3B719B-2AE7-4A9A-937C-D2C3B11B07FEQ35580474-216739EA-9763-41B3-AEC2-A3DF333DF294Q35626561-3C1F56AA-3DE4-48B1-A0A9-DC12FA396B65Q35752619-F0299BFB-09F1-4647-B0C7-1267FD5F3DC4Q35763966-284DEF2C-2B7F-45BE-9C8E-8C2FCCE3EB6FQ35925710-A1EB0F77-9A12-4935-A438-0B2A0EE1BB10Q36589956-19FB9FC1-27F8-48AE-8F18-4DFF52491DAAQ36679440-15B78799-D76B-4C55-99CA-FEEB66090893Q36727015-58ACE929-6A0A-4832-81EF-A0AF796E6394Q36787291-56AE670F-882E-4AA9-B354-6D81A152835C
P2860
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Pharmacodynamics of chimeric g ...... igh-risk coronary angioplasty.
@en
Pharmacodynamics of chimeric g ...... igh-risk coronary angioplasty.
@nl
type
label
Pharmacodynamics of chimeric g ...... igh-risk coronary angioplasty.
@en
Pharmacodynamics of chimeric g ...... igh-risk coronary angioplasty.
@nl
prefLabel
Pharmacodynamics of chimeric g ...... igh-risk coronary angioplasty.
@en
Pharmacodynamics of chimeric g ...... igh-risk coronary angioplasty.
@nl
P2093
P50
P356
P1433
P1476
Pharmacodynamics of chimeric g ...... igh-risk coronary angioplasty.
@en
P2093
B S George
D J Kereiakes
H F Weisman
J D Talley
J E Tcheng
N S Kleiman
P304
P356
10.1161/01.CIR.90.4.1757
P407
P577
1994-10-01T00:00:00Z